Study IPI-145-23 is an international, multicenter, open-label, single-arm, Phase 2 study designed to evaluate the long-term safety, clinical activity and overall survival data of duvelisib in patients with hematologic malignancies. Only subjects who have participated in a previous duvelisib study that are approved by the sponsor will be allowed to enroll in the study.